Insider · CIK 0001486373
Douglas G. Cole
Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Douglas G. Cole files SEC Form 4 as director at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Douglas G. Cole has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 11, 2023 | DNLI Denali Therapeutics Inc. | 102,240 0.07% of outstanding | $2.1M | Oct 11, 2023 | $231k |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 17, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
Questions about Douglas G. Cole
Answered from the filings on this page, as of the latest one.
Is Douglas G. Cole buying or selling?
Douglas G. Cole has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Douglas G. Cole's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas G. Cole has 0.
Where does Douglas G. Cole file Form 4?
Douglas G. Cole has filed Form 4 at FHTX (Foghorn Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.